Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare but serious cancer of the immune system. Since its first description in clinical literature, it has transformed the regulatory landscape of plastic surgery and breast reconstruction.
A common area of patient confusion is the difference between BIA-ALCL and traditional breast cancer. BIA-ALCL is not a breast cancer (which arises from the epithelial cells of the breast ductal or lobular tissue). Rather, it is a non-Hodgkin T-cell lymphoma—a cancer of the lymphatic cells—that develops within the fibrous scar capsule that the body naturally forms around a breast implant.
This guide provides an evidence-based review of BIA-ALCL. We detail its pathophysiology, the specific link to textured implants (specifically Allergan Biocell surfaces), the 2019 global recall data, clinical symptoms, diagnostic steps, NCCN treatment guidelines (complete en-bloc capsulectomy), and the FDA's current stance on proactive removal.
The Core Medical Brief Above the Fold
For patients seeking immediate safety answers, the key clinical facts are summarized below:
- Etiology: BIA-ALCL is almost exclusively linked to textured breast implants (not smooth implants). The textured surface is believed to cause chronic mechanical friction, tissue abrasion, and bacterial biofilm accumulation, driving chronic inflammation that triggers T-cell malignant transformation.
- The Allergan Biocell Link: The primary driver of cases globally is the Allergan (now AbbVie) BIOCELL textured surface, which accounts for approximately 85% of all reported cases. This led to a global FDA recall in July 2019.
- Symptoms: The most common symptom is sudden, delayed swelling or asymmetry in one breast, occurring 1 to 10 years (median ~8 years) after surgery, caused by fluid collection (late-onset seroma) around the implant.
- Treatment: If diagnosed early, BIA-ALCL is highly treatable and often curable. The primary treatment is surgical: removal of the breast implant and a complete en-bloc capsulectomy (removing the implant and the entire surrounding fibrous capsule as one intact unit). Advanced cases may require chemotherapy, targeted therapy (brentuximab vedotin), or radiation.
- Proactive Removal: The FDA and major plastic surgery societies do not recommend proactive implant removal for patients who do not have symptoms (such as swelling, lumps, or pain). The risk of surgical complications from explantation exceeds the lifetime risk of developing BIA-ALCL, which remains rare.
Pathophysiology and the Surface Texturing Connection
To understand how a breast implant can trigger a lymphatic cancer, we must look at the biology of the scar capsule and the engineering of implant surfaces.
The Scar Capsule and Foreign Body Response
When a breast implant (saline or silicone) is placed in the body, the immune system recognizes it as a foreign material. The body initiates a foreign body response, laying down a wall of dense, fibrous collagen tissue around the implant. This wall is called the scar capsule.
In BIA-ALCL, the malignant T-cells originate within this capsule or the fluid that accumulates between the implant surface and the capsule wall.
Surface Texture Classifications: The ISO 14607 Standard
The International Organization for Standardization (ISO) 14607 standard classifies breast implant surfaces based on surface roughness (measured as $Ra$ or average roughness in micrometers):
- Smooth Surfaced ($Ra < 10\ \mu\text{m}$): Have a slick, non-textured surface. There are no confirmed cases of BIA-ALCL occurring in patients who have only had smooth implants throughout their surgical history.
- Microtextured ($Ra = 10\text{ to }50\ \mu\text{m}$): These feature a fine, velvet-like texture (e.g., Mentor Siltex). They carry a very low risk of BIA-ALCL, though cases have occurred.
- Macrotextured ($Ra > 50\ \mu\text{m}$): These feature a rough, sandpaper-like or polyurethane-coated surface. Under this category sit the Allergan BIOCELL surface (roughness ~80–150 $\mu\text{m}$ created by a salt-loss process) and Polytech Polyurethane implants. Macrotextured implants carry the highest statistical risk of BIA-ALCL.
Pathogenesis: A Multi-Factorial Model
The prevailing scientific theory for the pathogenesis of BIA-ALCL involves a multi-factorial model:
- High Surface Area and Friction: Macro-textured surfaces have a much larger surface area than smooth surfaces. This leads to continuous mechanical friction against the surrounding tissue capsule, shedding silicone elastomer particles and causing chronic tissue abrasion.
- Bacterial Biofilm Accumulation: The deep crevices in macro-textured shells provide an ideal environment for bacteria (especially gram-negative bacilli, such as Ralstonia pickettii and Pseudomonas aeruginosa) to colonize and form a protective biofilm.
- Chronic Immune Stimulation: The combination of mechanical wear and subclinical bacterial infection creates persistent, chronic antigen stimulation. This drives a continuous influx of T-helper 1 (Th1) and Th17 inflammatory cells.
- Malignant Transformation: Over several years, this chronic inflammatory state can trigger genetic mutations (such as JAK1/STAT3 pathway mutations) in localized T-cells, leading to the clonal expansion of malignant, CD30-positive, ALK-negative T-cells.
The 2019 Allergan BIOCELL Global Recall: The Data Registry
The association between BIA-ALCL and Allergan's BIOCELL texturing is the most significant regulatory event in modern implant history.
Recall Registry Analysis
To verify the scope of this regulatory action, we queried the FDA device recall database. Under product code FTR (Prosthesis, Breast, Noninflatable, Internal, Silicone Gel-Filled) and Allergan PLC, the database logs the exact recall codes and dates.
On July 24, 2019, the FDA requested that Allergan recall all BIOCELL textured breast implants and tissue expanders. The recall registry logs 12 Allergan FTR recalls in total — 10 initiated on that exact date (Z-2452 through Z-2465, all carrying the status "Open, Classified"), plus two later labeling recalls (Z-0700 and Z-0701, initiated in November 2019). The 10 recalls from July 24, 2019 cover these BIOCELL device families:
- Z-2452-2019: Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants (Biocell Low Height Low Projection).
- Z-2453-2019: Natrelle Inspira Silicone-Filled Breast Implants.
- Z-2454-2019: Natrelle and McGhan Silicone-Filled Breast Implant BioCell Round Moderate Profile.
- Z-2459-2019: McGhan BioDIMENSIONAL Silicone-Filled Breast Implants (Style 153).
- Z-2460-2019: Natrelle and McGhan 410 TruForm 2 (Soft Touch) BIOCELL breast implants (Styles LL, LM, LF, ML, MM, MF, FL, FM, FF).
- Z-2461-2019: Natrelle 510 TruForm Dual-Gel BIOCELL implants (Styles LX, MX, FX).
- Z-2462-2019: Natrelle and McGhan Silicone-Filled Breast Implants (TruForm 2 Soft Touch, BIOCELL, Styles 110 Soft Touch and 120 Soft Touch).
- Z-2463-2019: Komuro Soft Touch BIOCELL INTRASHIEL BioDIMENSIONAL breast implants (Styles KML, KMM, KLL, KLM).
- Z-2464-2019: Ritz Princess Soft Touch BIOCELL INTRASHIEL BioDIMENSIONAL breast implants (Styles RML, RMM, RFL, RFM).
- Z-2465-2019: Natrelle 150 Full Height and Short Height BIOCELL INTRASHIEL BioDIMENSIONAL breast implants.
This recall meant that these devices could no longer be sold or implanted. For a wider perspective on how this fits into Allergan's overall regulatory history, you can review our summary of the Allergan aesthetics portfolio approvals and recalls.
The FDA Medical Device Reports (MDR) Tally
As of the FDA's most recent published surveillance update (June 30, 2024), the raw numbers compiled by the agency's Medical Device Reporting programs are:
- Total MDR Cases: 1,380 unique reports of BIA-ALCL worldwide.
- Deaths: 64 reported deaths among those MDRs (MDRs are submitted reports and are not all independently verified as confirmed BIA-ALCL deaths).
- Texturing Correlation: Of the cases where the implant surface type was specified, roughly 96% involved textured implants (the FDA's table lists 1,010 textured versus 40 smooth).
- Manufacturer Correlation: In cases where the manufacturer was identified, about 85% of patients had Allergan BIOCELL textured implants.
Symptoms and Clinical Presentation: What to Watch For
BIA-ALCL is characterized by a long latency period. The median time from implant surgery to diagnosis is 8 years, with cases presenting anywhere from 1 to 24 years post-implantation.
Primary Warning Signs
- Late-Onset Seroma (Fluid Collection): This is the presenting symptom in approximately 70% to 80% of patients. A late-onset seroma is a sudden accumulation of fluid between the implant shell and the scar capsule that occurs at least one year (and typically several years) after surgery. It presents as rapid, painless breast enlargement, asymmetry, or a feeling of fullness in one breast.
- Palpable Mass (Lump): Present in about 8% to 20% of cases. A firm, palpable tumor mass may grow within the fibrous capsule or extend into the surrounding breast tissue.
- Capsular Contracture: Sudden, unexplained hardening of the breast or pain in a breast that was previously soft and pain-free.
- Skin Changes: Redness, skin warmth, or itching over the breast skin.
- Lymphadenopathy: Enlarged lymph nodes in the axilla (underarm) on the side of the implant.
Diagnostic Pathway: Step-by-Step
If you present with a late-onset seroma or a palpable mass around an implant, your clinical team must follow a strict diagnostic sequence to rule out or confirm BIA-ALCL.
Diagnostic Protocol for Late Seroma
│
▼
High-Resolution Ultrasound
│
┌─────────────────────────┴─────────────────────────┐
▼ ▼
Fluid Collection Present (>50 mL) Solid Mass Only
│ │
▼ ▼
Ultrasound-Guided Aspiration Core Needle Biopsy
│ │
└─────────────────────────┬─────────────────────────┘
▼
Pathological Evaluation
- Cytology & Cell Block
- CD30 Immunohistochemistry
- ALK Gene Expression (Typically Negative)
- Imaging (High-Resolution Ultrasound): The first-line diagnostic test. Ultrasound is highly sensitive at detecting fluid collections (seromas) and solid masses around the implant. MRI of the breast may be ordered for staging if a mass is detected.
- Fluid Aspiration (Aspirate Analysis): If a fluid collection of >50 mL is identified, the provider performs an ultrasound-guided fine-needle aspiration (FNA) of the fluid.
- Pathology and the CD30 Marker: The fluid is sent for cytopathology. The pathology lab evaluates the cells using immunohistochemistry:
- CD30 (Ki-1 antigen): BIA-ALCL cells strongly express CD30, a cell-surface marker associated with activated T-lymphocytes. A positive CD30 stain is required for diagnosis.
- ALK (Anaplastic Lymphoma Kinase): BIA-ALCL is ALK-negative (unlike systemic ALCL, which is often ALK-positive).
- Core Needle Biopsy: If a solid mass is present without fluid, a core needle biopsy of the mass is performed.
TNM Staging and Prognosis
BIA-ALCL is staged using a modified TNM (Tumor, Node, Metastasis) staging system developed by the MD Anderson Cancer Center.
| Stage | Description | 5-Year Survival Rate |
|---|---|---|
| Stage IA | Disease confined strictly to the peri-implant fluid (effusion). | ~98%–100% |
| Stage IB | Disease invades the fibrous capsule but remains localized (infiltrative). | ~95%–98% |
| Stage IC | Disease extends beyond the capsule into the local breast parenchyma. | ~90%–95% |
| Stage IIA | Disease involves a single regional lymph node (typically axillary). | ~80%–85% |
| Stage IIB | Disease involves multiple regional lymph nodes. | ~70%–75% |
| Stage III | Systemic metastasis to distant organs (lung, bone, liver). | ~50% or less |
The vast majority of patients present at Stage IA or IB, which is fully curable with surgery alone.
Operative Protocol: Inside the OR during En-Bloc Capsulectomy
For patients undergoing surgical treatment or prophylactic removal, understanding what occurs in the operating room is essential. An en-bloc capsulectomy is a demanding, meticulous procedure.
Step-by-Step Surgical Technique
- Patient Positioning and Anesthesia: The surgery is performed under general anesthesia. The patient is placed in the supine position with the arms extended at 90 degrees to expose the axillae and lateral chest wall.
- Incision Selection: The surgeon typically utilizes the previous inframammary fold (IMF) incision. This provides the most direct access to the lower border of the capsule and allows for complete visualization of the chest wall.
- Dissection Plane: The surgeon identifies the dissection plane outside the capsule.
- If the implant is subglandular (above the muscle), the dissection is carried out between the breast gland tissue and the capsule.
- If the implant is subpectoral (below the muscle), the dissection must separate the capsule from the pectoralis major muscle and the ribs/intercostal muscles.
- En-Bloc Excision: Using electrocautery or cold dissection, the surgeon meticulously separates the entire capsule from the surrounding breast tissue and chest wall, keeping the capsule completely intact. If a tear occurs, the surgeon immediately staples or clamps it to prevent fluid leakage. The implant and capsule are removed as a single, sealed specimen.
- Pocket Irrigation: The pocket is irrigated thoroughly. Surgeons routinely use a triple-antibiotic solution (commonly consisting of bacitracin, polymyxin B, and neomycin) or a dilute povidone-iodine solution (Betadine) to eliminate residual bacterial biofilm.
- Drain Placement: Jackson-Pratt (JP) suction drains are placed in the cavity to collect residual fluid and blood, minimizing seroma formation post-op. The drains are typically kept in place until output is less than 30 mL per day for two consecutive days.
For more details on recovery, risks, and postoperative expectations, read our full guide on breast implant removal.
Proactive Removal: Understanding the FDA Position
For patients who have textured implants (including Allergan BIOCELL) but are currently asymptomatic (no pain, swelling, or lumps), the question of proactive removal is a major source of anxiety.
The FDA Guidance: Do Not Remove Asymptomatic Implants
The FDA, the American Society of Plastic Surgeons (ASPS), and the Aesthetic Society recommend against the proactive removal of textured implants in asymptomatic patients.
The rationale is based on a risk-benefit analysis:
- Low Lifetime Risk: The lifetime risk of developing BIA-ALCL in patients with textured implants is low, estimated to range between 1 in 2,200 and 1 in 86,000 depending on the specific implant model. For Allergan BIOCELL, the risk is higher (roughly 1 in 2,200 to 1 in 3,000) but remains low.
- Surgical Risks: Explant surgery and capsulectomy are major surgical procedures performed under general anesthesia. They carry a baseline rate of surgical complications, including hematoma (collection of blood), seroma, wound infection, skin necrosis, breast asymmetry, and risks associated with general anesthesia. The statistical risk of experiencing a surgical complication from prophylactic removal is higher than the statistical risk of developing BIA-ALCL.
- Excellent Prognosis: Because the disease is slow-growing and highly curable through surgery if caught early, the FDA advises that careful monitoring (vigilant tracking of breast changes) is safer than prophylactic surgery.
Financial and Emotional Costs of Screening
- Routine Ultrasounds: For asymptomatic patients with textured implants, plastic surgeons recommend an ultrasound scan every 2 years. These scans typically cost $200 to $500 out of pocket, as insurance companies do not cover screening for asymptomatic recalls.
- The Psychological Toll: Many patients suffer from "implant anxiety" after learning about the recall. It is important to discuss these concerns with a board-certified plastic surgeon. If the anxiety severely impacts quality of life, prophylactic explantation may be considered, but the patient must prepare to cover the surgical costs (typically $6,000 to $12,000) out of pocket.
The PROFILE Registry and National Surveillance
In the United States, tracking the safety of breast implants is supported by the Patient Registry in Implant System Safety and Efficacy (PROFILE). Established as a collaborative partnership between the American Society of Plastic Surgeons (ASPS), the Plastic Surgery Foundation (PSF), and the FDA, the PROFILE registry is designed to identify, collect, and track every confirmed case of BIA-ALCL in the country.
- Clinical Reporting: When a plastic surgeon or pathologist diagnoses a patient with CD30-positive, ALK-negative breast implant-associated T-cell lymphoma, they are legally and ethically requested to submit the case to the PROFILE registry. The registry collects data on the patient's surgical history, the brand and model of the implant, the texture type, the staging of the lymphoma, the surgical treatment rendered, and the clinical outcomes.
- Safety Signals: By centralizing this data, the PROFILE registry allows epidemiologists to detect subtle shifts in safety signals, such as if a newer microtextured or smooth implant starts showing cases. It also provides the longitudinal data used by the FDA to update its Medical Device Reports (MDR) tallies.
Long-Term Clinical Monitoring Protocol
For patients with textured breast implants, a proactive, lifetime monitoring protocol is the widely recommended clinical protocol.
- Annual Clinical Exams: Patients should undergo a clinical breast exam performed by a physician (plastic surgeon or gynecologist) every year. The provider checks for breast asymmetry, capsule firmness, or palpable masses in the breast and axillary folds.
- Regular Self-Inspection: Patients must perform monthly breast self-exams. They should look for changes in size, localized swelling, pain, or hardening.
- High-Resolution Imaging: Routine screening mammograms (which primarily evaluate the breast tissue for epithelial breast cancer) are not sufficient to screen for BIA-ALCL. If a patient feels a change or has macrotextured implants, a high-resolution ultrasound is the screening modality of choice to check for subclinical peri-implant fluid collections.
- MRI Evaluation: In cases where ultrasound findings are equivocal, a breast MRI with and without contrast is performed to evaluate the integrity of the implant shell and the thickness of the surrounding capsule.
To read more about the tracking of breast implant safety via patient registries and clinical trials, see our summary of breast implant PMA approvals and market footprints and our review of breast implant adverse events in the FDA MAUDE database.
Frequently Asked Questions
Is BIA-ALCL fatal?
BIA-ALCL can be fatal if left untreated and allowed to spread systemically. However, it is a slow-growing disease. When caught early and treated with complete en-bloc capsulectomy, the prognosis is excellent, with a 5-year survival rate exceeding 95%. The 64 deaths reported to the FDA as of June 30, 2024 largely represent cases where diagnosis was severely delayed, allowing the lymphoma to invade the chest wall or spread to distant organs.
Can smooth implants cause BIA-ALCL?
There are no confirmed cases of BIA-ALCL occurring in patients who have only had smooth implants throughout their surgical history. In the rare cases where a patient with smooth implants was diagnosed with BIA-ALCL, a detailed review of their medical records usually revealed a prior history of having textured implants (which were later replaced with smooth ones), or the implants were determined to be micro-textured rather than truly smooth.
What is the lifetime risk of BIA-ALCL with textured implants?
The overall lifetime risk is estimated at 1 in 2,200 to 1 in 86,000 for patients with textured implants. For Allergan BIOCELL textured implants, the risk is at the higher end of the spectrum, estimated at approximately 1 in 2,200 to 1 in 3,000.
Does insurance cover explant surgery for BIA-ALCL?
- Confirmed Diagnosis: Yes. If a patient is diagnosed with BIA-ALCL (confirmed via cytology/CD30 stain), insurance and Medicare cover the explant surgery, capsulectomy, pathology fees, and any necessary adjuvant oncology therapies.
- Prophylactic (Proactive) Removal: If the patient has no symptoms and is seeking removal out of anxiety or peace of mind, insurance companies classify the surgery as cosmetic and elective, meaning it is not covered. Some manufacturers (including Allergan) have offered limited warranty programs to help offset the cost of replacement smooth implants, but they do not cover the surgeon's fees or operating room costs for asymptomatic patients.
Can I get BIA-ALCL from a silicone gel-filled implant, or only from saline?
You can get BIA-ALCL from both silicone and saline implants. The disease is linked to the textured surface of the outer elastomer shell, not the filling inside the implant. Both saline-filled and silicone gel-filled implants with textured shells carry the risk.
How long does it take for a seroma to form after breast augmentation?
- Early Seromas: Occur within the first few weeks after surgery and are typically a normal postoperative response to tissue dissection or bleeding. They resolve with rest or simple clinical aspiration.
- Late Seromas (BIA-ALCL Warning): Form at least one year after surgery, and most commonly present 5 to 10 years post-implantation. Any new, sudden fluid collection presenting years after surgery is considered abnormal and must be evaluated for BIA-ALCL.
Can I replace my recalled implants with smooth implants during the same surgery?
If you are asymptomatic and undergoing elective removal, yes, you can replace the textured implants with smooth ones during the same operative session. However, if you have a confirmed diagnosis of BIA-ALCL, immediate implant replacement is strictly contraindicated. The lymphoma must be treated first, and delayed reconstruction is typically scheduled 6 to 12 months after confirming complete remission.
Sources
- FDA Safety Communication on BIA-ALCL (FDA Tally & Allergan Recall): https://www.fda.gov/medical-devices/safety-communications/fda-requests-allergan-voluntarily-recall-natrelle-biocell-textured-breast-implants-and-tissue
- FDA Breast Implant Boxed Warning and Patient Decision Checklist (2021 Update): https://www.fda.gov/medical-devices/breast-implants/regulatory-history-breast-implants-fda
- Clemens MW, Jacobsen ED, Horwitz SM. 2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). Aesthetic Surgery Journal 2019;39(Supplement_1):S3–S13: https://academic.oup.com/asj/article/39/Supplement_1/S3/5304919
- American Society of Plastic Surgeons (ASPS) BIA-ALCL Resources & PROFILE Registry: https://www.plasticsurgery.org/patient-safety/breast-implant-safety/bia-alcl
- FDA — Questions and Answers About Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) (diagnosis, treatment, and risk Q&A): https://www.fda.gov/medical-devices/breast-implants/questions-and-answers-about-breast-implant-associated-anaplastic-large-cell-lymphoma-bia-alcl
